Pembrolizumab (Keytruda®) for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.

Assessment Status Assessment Process Complete
HTA ID -
Drug Pembrolizumab
Brand Keytruda®
Indication For the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.
Assessment Process
Rapid review commissioned 06/08/2015
Rapid review completed 13/08/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 02/11/2015
NCPE assessment completed 08/02/2016
NCPE assessment outcome Reimbursement not recommended

Technical Summary

The HSE has approved reimbursement following confidential price negotiations June 2016.